Press releases

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO has been terminated

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 25 May 2023. At the Annual General Meeting, the following principal resolutions were passed

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that new scientific data on melflufen has been accepted at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023. The data includes one clinical abstract on final efficacy and safety data from the phase 1/2 ANCHOR study, and one preclinical abstract on melflufen showing efficacy in association with decreased and mutated TP53 activity and enrichment of genes involved in DNA damage repair

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and safety data from the ANCHOR study has been accepted as a poster presentation at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes the report for the first quarter 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced that the company has decided to utilize the first tranche under the company's loan agreement with the European Investment Bank (EIB) and resolved on an issue of warrants

Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022 Annual Report has been published

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 25 May 2023 at 3 p.m. Registration for attendees will commence at 2.30 p.m

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company presents new scientific data on melflufen at the European Myeloma Network meeting in Amsterdam on April 20. The data includes one abstract on health-related quality of life outcomes from the phase 3 OCEAN study, and one abstract from the phase 3 LIGHTHOUSE study